The FDA granted fast track designation to ADI-001 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.
ADI-001 (Adicet Bio) is an allogeneic gamma-delta T-cell therapy derived from donor cells that is genetically engineered to express a CD20-directed chimeric antigen receptor.
The FDA’s fast track designation helps to expedite development, review and potential approval of treatments for serious or life-threatening diseases.
The investigational cell therapy is currently being evaluated as part of the GLEAN-1 trial, a phase 1, U.S.-based multicenter dose-escalation study to
FDA grants fast track designation to gamma-delta T-cell therapy for advanced lymphoma
The FDA granted fast track designation to ADI-001 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.
ADI-001 (Adicet Bio) is an allogeneic gamma-delta T-cell therapy derived from donor cells that is genetically engineered to express a CD20-directed chimeric antigen receptor.
The FDA's fast track designation helps to expedite development, review and potential approval of treatments for serious or life-threatening diseases.
The investigational cell therapy is currently being evaluated as part of the GLEAN-1 trial, a phase 1, U.S.-based multicenter dose-escalation study to